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Open access under CC BY license.Drugs are often used in combination and, for pharma-
cologists, the manner of their interactions can cast light
on drug mechanisms and biological processes. Here we
provide simplified descriptions of commonly used ana-
lytical methods for analysing drug combinations and
describe a new and practical experimental solution to
address the mechanistic question: ‘Do two channel-
blocking drugs bind at the same site?’ We define two
simple mathematical models that describe the effects of
two channel blockers acting simultaneously at either the
same (Syntopic Model) or different (Allotopic Model)
binding sites within a channel pore. We find that the
optimum concentrations of two drugs for distinguishing
between the two models are related to the mathematical
Golden Ratio.
Analysing drug combinations
Drug combinations are commonly used in clinical practice
to deliver therapeutic benefit beyond the use of single
treatments alone [1–4]. Pharmacologists also use drug
combinations to investigate drug mechanisms. For exam-
ple, Schild analysis, using an agonist and antagonist, may
reveal a competitive mechanism of action. However, such
combinations do not always generate easily interpretable
data. Much has been written on the analysis [5,6] and
definition of responses as additive, synergistic or antago-
nistic (Box 1). Two related approaches are isobolograms
(Box 2) and the Combination Index (CI) [7,8]. These
require the estimation of pairs of drug concentrations
that elicit equivalent responses. Such experiments are
time-consuming, may require substantial quantities of
drugs, and are conceptually operational rather than
mechanistic.
Here we describe a simple method for addressing the
question ‘Do two channel-blocking drugs bind at the same
site?’ We define two mechanistically distinct models: a
Syntopic Model with a single binding site for both drugs
and an Allotopic Model with two distinct drug binding sites
[9]. To distinguish between these models, concentrations of0165-6147
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synergism.drug are combined that, when used alone, cause inhibition
equal to the reciprocal of the Golden Ratio (61.8%) (Box 3)
[10]. This approach may be particularly useful where the
quantities of novel compounds are in limited supply or
where there are no high quality reporter ligands.
Theoretical modelling
Channel-blocking drugs are particularly well-suited for the
mechanistic analysis of drug combinations, because inhi-
bition of conductance is closely related to binding site
occupancy. More specifically, our analysis is based on
the following assumptions.
(i) Channel blockers reduce conductance to zero ‘much as
a cork stoppers a bottle’ [11] and do not induce
intermediate conductance states. It follows that at
sufficiently high concentrations they will abolish the
current response and at lower concentrations inhibi-
tion will be directly proportional to binding, as
observed with saxitoxin [12–15]. Hence, zero occu-
pancy results in zero inhibition (IN = 0) and 100%
occupancy results in complete inhibition (IN = 1).
(ii) Channels function independently of each other, such
that the activity of one channel is unaffected by the
binding of a blocker to another.
(iii) Blocker binding is non-cooperative with a Hill
coefficient of one. The mechanistic interpretation of
non-unity Hill coefficients is not straightforward [16].
(iv) Blockers do not modify channel gating, for example,
by changing the binding affinity or efficacy of a
channel agonist.
(v) Blockers bind non-selectively to open and closed
states.
(vi) Calculated block is assumed to be at dynamic
equilibrium.
Two distinct models for the simultaneous action of two
channel-blocking drugs are defined (Figure 1).
Allotopic Model
The Allotopic Model describes two drugs (A and B) that can
bind to different sites at the same time (Figure 1A). The
term ‘allotopic’ is used to indicate binding location [9]
rather than ‘allosteric’, which implies conformational dif-
ferences [17]. Here we assume that there is no allosteric
modulation. The case where the affinity of one blocker is
affected by the binding of the other is considered later.
Reversible interactions of drug A (and analogously for
drug B) with an ion channel may be modelled with a simpleTrends in Pharmacological Sciences, September 2013, Vol. 34, No. 9 481
Box 1. When two drugs meet – additivity, synergy and antagonism
When used in combination with itself, a drug’s response is
determined by its own concentration–response relationship. This is
Loewe Additivity [21] (Figure IA) and is analogous to our Syntopic
Model; viewed as an isobologram (Figure IB), a linear pattern is
revealed (Equation I). Bliss Independence is another model of drug
combinations [27] (Figure IC) and is analogous to our Allotopic Model;
in this case, the isobologram (Figure ID) reveals a non-linear pattern
(Equation II). Both of these models may be considered additive (in
both cases, the Combination Index [CI] = 1). When drug combinations
result in greater responses than those predicted, synergy is indicated
(CI < 1), whereas a response that is less indicates antagonism (CI > 1).
However, for any drug pair it may be difficult to decide which of these
models should be the reference for additivity. In the figure, for all
drugs EC50 = 1 mM and Hill coefficient = 1.
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Non-linear isoboles
Figure I. Different models to express drug interactions. (A) 3D plot illustrating Loewe Additivity as expected when the same drug (A) is applied on both horizontal axes.
(B) Colour isobologram of Loewe Additivity showing linear isoboles. Equation I describes the isoboles for paired concentrations of drug A ([A1] and [A2]) that give a
response r when used together. Ar is the concentration of A alone that elicits response r. Equation I also determines the Combination Index (CI) for mutually exclusive
drugs. In this case, CI = 1. (C) 3D plot illustrating Bliss Independence. In Bliss’ original description, a combination of two LD50 concentrations of independently acting
poisons results in a mortality of 75%. (D) Colour isobologram of Bliss Independence showing non-linear isoboles. Equation II describes the isoboles for paired
concentrations of drugs X and Y that give a response r when used together. Xr and Yr are the concentrations of X and Y alone that elicit response r. Equation II also
determines the CI for mutually non-exclusive drugs. In this case, CI = 1.
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PA ¼ ½A=Ka½A=Ka þ 1 ; [1]
where PA is the proportion of binding sites occupied by
drug A (0  PA  1), [A] is the concentration of drug A, and
Ka is the equilibrium dissociation constant of drug A.
Because drugs A and B bind independently to different
sites, when used together the level of inhibition will be482governed by laws of probability for independent, mutually
non-exclusive events. The level of conductance will be equal
to the product of the proportionate conductances in the
presence of each drug alone. For example, if drug A alone
reduces conductance by 30% (conductance = 0.70) and drug
B reduces conductance by 40% (conductance = 0.60), con-
ductance in the presence of the same concentrations of drugs
A and B together would be 70%  60% = 42% (inhibi-
tion = 58%) (Figure 1C). Therefore, the overall level of
Box 2. What is an isobologram?
An isobologram (Figure IA) is one of three possible 2D views of a 3D
surface representing the response to two drugs, in this case an
agonist A and a competitive antagonist B. The other 2D views show
Schild (Figure IB) [28] and Cheng–Prusoff (Figure IC) analyses [29].
Isobolograms are often shown with linear concentration scales and
may have characteristic patterns. For competitive antagonism, the
contours (or isoboles) are straight lines that converge where [A] = 0
and [B] = –dissociation constant (Figure IA). In the figure, A is the
agonist: Maximum response = 100%, pA50 = 6, Hill coefficient = 1; and
B is the competitive antagonist: pKb = 6.
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Figure I. Three possible 2D views of a 3D surface representing the response to two drugs. (A) Viewed along the z-axis, the 3D plot reveals an isobologram in which the
coloured contours represent equal response levels. (B) Viewed along the x-axis, the 3D plot of competitive antagonism appears as a Schild analysis in which agonist–
response curves are contour lines representing equal antagonist concentrations. (C) Viewed along the y-axis, the 3D plot of competitive antagonism appears as a
Cheng–Prusoff analysis in which antagonist–inhibition curves are contour lines representing equal agonist concentrations.
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Box 3. Phi-macology?
The Golden Ratio (Figure IA) has fascinated philosophers and
scientists for centuries [10]. The name ‘phi’ (f) is derived from the
Greek sculptor Phidias who, it is claimed, made use of it in his work.
f has been associated with many natural phenomena, including
nucleotide frequency in genomes [30], magnetic models of quantum
physics [31], and plant phyllotaxis [32]. However, f emerges most
convincingly in mathematics and geometry. Around 300 BC, Euclid
defined extreme and mean ratios using a segmented line (Figure IB).
To our knowledge, no pharmacological association with f has been
described and yet it appears in the simplest of pharmacological
models, the Hill–Langmuir equation (Figure IC) [18], as well as our
Allotopic and Syntopic Models (Figure ID).
It is not obvious that f should form part of the answer to the
question: ‘‘Do two channel-blocking drugs bind at the same site?’’
Its unexpected appearance might invite speculation about further
biological significance. However, whether simple pharmacological
processes could provide a mechanistic basis for the emergence of f
in biological phenomena remains to be seen.
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Figure I. The Golden Ratio. (A) Arithmetical representation of the Golden Ratio
(f) and its reciprocal (F). (B) Euclid’s geometrical representation of the Golden
Ratio. (C) In a Hill–Langmuir concentration–response curve where the Hill
coefficient = 1, the Golden Ratio is found at two locations either side of the
central intersection between the dissociation constant (Kd) and 50% binding.
(D) The relationship between inhibition by channel-blocking drugs acting alone
and as a pair, in the Allotopic and Syntopic Models. The maximum difference
between the two models occurs when inhibition by a single drug is equal to F.
At this point, the sum of allotopic and syntopic inhibitions is equal to f.
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484inhibition INA;B
 
would be:
INA;B ¼ 1  1  INAð Þ 1  INBð Þ½ ; [2]
which simplifies to:
INA;B ¼ INA þ INB  INAINB: [3]
Syntopic Model
The Syntopic Model describes two drugs (X and Y) that
share a binding site such that when one binds the other
cannot (Figure 1B). This is defined by the familiar equation
for competitive interactions [19,20]:
PX ¼ ½X =Kx½X =Kx þ ½Y =Ky þ 1 ; [4]
where PX is the proportion of binding sites occupied by
drug X (0  PX  1), [X] and [Y] are the concentrations of
drugs X and Y, and Kx and Ky are the equilibrium dissoci-
ation constants for drugs X and Y, respectively. Total
channel occupancy by drugs X and Y (PX,Y) is therefore:
PX;Y ¼ ½X =Kx þ ½Y =Ky½X =Kx þ ½Y =Ky þ 1 : [5]
In the presence of drug X (and analogously for drug Y),
the level of inhibition INXð Þ may be derived from Equation 1
as follows:
½X =Kx ¼ INX
1  INX : [6]
Unlike the Allotopic Model, binding of drug X changes in
the presence of drug Y (Figure 1D). However, Equation 6
can be substituted into Equation 5 to define inhibition in
the presence of drugs X and Y together INX;Y
 
, expressed
in terms of inhibition in the presence of either drug X or Y.
INX;Y ¼
INX
1  INX
 
þ INY
1  INY
 
INX
1  INX
 
þ INY
1  INY
 
þ 1
; [7]
which simplifies to:
INX;Y ¼ INX þ INY  2INXINY
1  INXINY : [8]
Both the Allotopic and the Syntopic Models are repre-
sented mathematically in terms of drug concentration and
dissociation constants in Figure 1E,F.
Theoretical evaluation of the two models
The predicted difference in inhibition caused by two drugs
acting allotopically or syntopically is small and apparent
only at certain concentration combinations (Figure 2).
Therefore, drug concentrations must be carefully chosen
to distinguish between the models. This difference INDIFFð Þ
is as follows:
INDIFF ¼ IN1IN2 1  IN1ð Þ 1  IN2ð Þ
1  IN1IN2 ; ð¼ ½3  ½8Þ [9]
where IN1 and IN2 are the levels of inhibition induced by
the two drugs when acting alone.
The maximum difference between the two models
occurs when the first partial derivatives of Equation 9
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Figure 1. An illustration of channel occupancy. The Allotopic Model (A) describes the binding of two channel-blocking drugs (A and B) to separate and independent binding sites
within a channel. The Syntopic Model (B) describes the binding of two channel-blocking drugs (X and Y) that share a common binding site where the binding of one blocker
prevents binding of the other; it is a model of competitive binding. On application of one drug alone, channel occupancy may be modelled with the dissociation constant. On
application of two drugs together, overall channel occupancy will depend on the dissociation constants and whether the drugs bind allotopically or syntopically. Only channels
that have no drug bound pass current. (C) In the presence of both drugs together, the occupancy relationship between a binding site and its ligand remains unchanged in the
Allotopic Model; occupancy by drug A is the same in the presence of drug A alone or drugs A and B. (D) In the Syntopic Model, occupancy by drug X differs depending on whether
it is applied alone or in combination with drug Y. (E,F) Mathematical models relating overall occupancy to drug concentrations and dissociation constants. Kx = dissociation
constant of drug X; OccX = proportion of channels occupied by drug X in the presence of X alone; OccX(+Y) = proportion of channels occupied by drug X in the presence of X and Y;
Occtotal = proportion of channels occupied by any drug. (C) and (D) represent the situation when the concentration of each drug is equal to its dissociation constant.
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Figure 2. Comparison of Allotopic and Syntopic Models. The effects of two channel-blocking drugs acting (A) allotopically (drugs A and B) or syntopically (drugs X and Y).
The difference between these two models is small and most clearly seen in a 2D view (B) of the response surface along the plane (grey shading in A) where [Drug 1] = [Drug
2]. The maximum difference between the models is approximately 9% and occurs when concentrations of drug equal to the dissociation constant multiplied by f are used
(Box 3). In these illustrations, the dissociation constants (Kd) are 1 mM and the Hill coefficients are 1. Hence, when used alone, 1.618 mM of each drug causes inhibition of
61.8% and when used together the total drug concentration (3.24 mM) causes 85.4% inhibition in the Allotopic Model and 76.4% inhibition in the Syntopic Model (Box 3).
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Figure 3. Inhibition of the 5-hydroxytryptamine type 3 (5-HT3) receptor by channel-blocking drugs. 5-HT3 receptors were activated with supra-maximal concentrations of 5-
HT and inhibited with bilobalide (BB), ginkgolide B (GB) and diltiazem (DTZ) (each of which has a Hill coefficient of one [33], fulfilling assumption (iii) – see text) acting either
alone or in combination. Concentrations of the drugs were selected to achieve inhibition of 61.8% when acting alone. Each panel shows observed data for the drugs acting
alone (white bars) and for the same drugs acting together (black bars). The grey bars show the predicted levels of inhibition for the Allotopic and Syntopic Models,
calculated using the experimental levels of inhibition caused by the drugs acting alone. Data are shown as the mean  standard error of the mean (sem) and two-way
(Figure legend continued on the bottom of the next page.)
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zero. Partial differentiation with respect to IN1 gives:
d INDIFFð Þ
d IN1ð Þ ¼
IN2 1  IN2ð Þ IN21IN2  2IN1 þ 1
 
1  IN1IN2ð Þ2
: [10]
An analogous expression may be derived for IN2. Solving
Equation 10 for derivative = 0 gives two trivial solutions:
IN2 = 0 and IN2 = 1. A more useful solution emerges from
equating the third expression in the numerator to zero:
IN21IN2  2IN1 þ 1 ¼ 0: [11]
Given the symmetry between IN1 and IN2, a solution may
be found when IN1 = IN2:
IN31  2IN1 þ 1 ¼ IN21 þ IN1  1
 
IN1  1ð Þ ¼ 0: [12]
The solution to this expression is the reciprocal of
the universally known Golden Ratio [10]: In1 ¼ In2 ¼
F ¼ ﬃﬃﬃ5p  1 =2  0:618.
Therefore, to maximise the chance of observing a differ-
ence between the two models, concentrations of channel-
blocking drugs should be used that cause 61.8% inhibition
when acting alone. These concentrations are equal to
IC50  f. At these concentrations, the predicted level of
inhibition is 0.85 in the Allotopic Model and 0.76 in the
Syntopic Model, giving a maximum possible INDIFF  0.09
(Box 3). INDIFF  0.09 (Box 3).
Experimental design, statistical analysis and
interpretation
To distinguish between allotopic and syntopic interactions,
concentrations of two drugs are selected that cause 61.8%
inhibition when used alone. The observed responses to
these concentrations are then used to calculate predicted
values for the Allotopic and Syntopic Models. These pre-
dicted values are compared with experimentally observed
inhibition when both blockers are applied together.
Because the largest expected difference between the
Allotopic and Syntopic Models is only 9%, its successful
detection will depend on the variability of the data, and
statistical analysis is necessary to compare the predicted
and observed dual inhibition values. Deviations from the
ideal level of inhibition by a single drug may be accommo-
dated using a two-way analysis of variance (ANOVA) that
treats this variability as a random effect, and the difference
between the observed dual inhibition and the two predic-
tions as a fixed effect. A significant overall ANOVA result is
always expected because the allotopic and syntopic pre-
dictions are fundamentally different; therefore, non-signif-
icance is indicative of insufficient statistical power, which
can be addressed by further experimental repeats. A post
hoc Dunnett’s test in which the observed dual inhibition is
the reference value is suitable for evaluating the allotopic
and syntopic predictions.
When the observed data differ significantly from one
prediction but not from the other, this suggests that thatanalysis of variance (ANOVA) was used to determine whether there was a difference be
compare the syntopic and allotopic predictions with the observed dual inhibition data.
matched the prediction made by the Syntopic Model but differed from the Allotopic Mod
also closely matched the predicted Syntopic Model but differed from the Allotopic Mode
Allotopic Model and differed significantly from the Syntopic Model.the drugs act according to the latter model. If the observed
inhibition is significantly different to both predictions, this
suggests that the drugs bind allotopically, but with an
allosteric effect.
Experimental evaluation: the 5-HT3 receptor as a model
system
To test the utility of this method, we examined channel
blockade of 5-hydroxytryptamine type 3 (5-HT3) receptors
using bilobalide (BB), ginkgolide (GB) and diltiazem (DTZ)
(Figure 3). Two separate preparations of the same drug
would conform to the Syntopic Model, consistent with the
model of Loewe (Box 1) [21]. As expected, the response to
two separate concentrations of DTZ matched the Syntopic
Model but differed significantly from the Allotopic Model
(Figure 3A). Similarly, inhibition by BB and GB was
consistent with published studies showing that these
ligands share the same binding site (Figure 3B) [22]. By
contrast, BB and DTZ, which have different channel bind-
ing sites [22], gave experimental values matching the
Allotopic Model (Figure 3C).
Relationship to other methods for analysing drug
combinations
Much has been written on the analysis of drug combina-
tions [5,23] and the challenge of defining drug synergy
[3,5]. Here, we consider how our question: ‘Do two channel-
blocking drugs bind at the same site?’ might have been
addressed by other methods.
Isobolograms are often used to analyse drug combina-
tions [8] and their patterns may reflect particular mecha-
nisms of action (Boxes 1 and 2). Based on the concept of
drug equivalence, this approach requires the identification
of multiple pairs of drug concentrations that result in
similar levels of response. This could be impractical where
time and drug quantities are limited.
The Median Effect Plot [7] is identical to a Hill Plot
and can therefore be used to determine Hill coefficients
and IC50/EC50 (median effect) values for concentration–
response relationships. Subsequent calculation of a Com-
bination Index (CI) [24] uses equations that closely resem-
ble those for isobolograms (Box 1): CI = 1 indicates
additivity, CI < 1 synergy, and CI > 1 antagonism. Like
individual isoboles, CI relates to a particular level of
response. The analysis requires a median effect plot for
each drug alone and for both drugs together in a fixed ratio
and defines ‘mutually exclusive’ and ‘mutually non-exclu-
sive interactions that resemble our Syntopic and Allotopic
Models. However, there are analytical problems with this
approach that have been described elsewhere [5,6].
Attempts have been made to interpret drug–drug inter-
actions mechanistically [1]. However, drug combination
analyses such as those described above have typically been
used in clinical contexts to maximise therapeutic benefit
and minimise adverse effects by combining drugs. They
imply little about drug mechanisms [8]. Our approach istween the three sets of dual inhibition data. A post hoc Dunnett’s test was used to
 (A) Inhibition caused by two separate preparations of diltiazem (DTZ1 and DTZ2)
el, as expected for two preparations of the same drug. (B) Inhibition by BB and GB
l. Inhibition by a combination of BB and DTZ (C) was most closely predicted by the
487
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nistic.
Concluding remarks
Compared with other methods, our approach requires
minimal quantities of drug. Nevertheless, it offers insight
into the binding sites of channel-blocking drugs by focus-
sing on the point where the difference between the Allo-
topic and Syntopic Models is greatest. However, it would be
naı¨ve to suppose that these models adequately represent
all possible situations where two channel-blocking drugs
act simultaneously. Our Allotopic Model assumes that
drugs bind independently, although interactions may oc-
cur. Allosteric effects induced by the binding of one drug
may change the affinity of the other. This has been mod-
elled using an affinity-modifying factor, often denoted as a
[25,26]. A value of a = 0 is equivalent to our Syntopic Model
and a = 1 to our Allotopic Model. Allosteric effects may be
indicated when the observed dual inhibition differs from
both syntopic and allotopic predictions, equivalent to a 6¼ 1.
Whether this effect is detectable will depend on its magni-
tude. At one extreme, the binding of one drug could allo-
sterically prevent the binding of the other (i.e., a = 0) and
this would be indistinguishable from the Syntopic Model,
although similar outcomes would also arise from estab-
lished methods for detecting competitive antagonism [25]
such as Schild Analysis.
Future developments will incorporate the estimation of
a in this simple approach. Preliminary modelling also
indicates that, under appropriate conditions, our method
can work for blockers that bind selectively to open channels
and is not restricted to non-selective blockers. As a practi-
cal experimental method, non-labelled ligands may be
used to reference binding sites, thereby eliminating the
requirement for suitably labelled probes. Multiple pair-
wise comparisons would enable the mapping of channel
binding sites, which may be useful for screening series of
novel compounds, particularly those in scarce supply.
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